A detailed history of Kayne Anderson Rudnick Investment Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Kayne Anderson Rudnick Investment Management LLC holds 27,836 shares of BMY stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,836
Previous 28,668 2.9%
Holding current value
$1.6 Million
Previous $1.19 Million 21.01%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $32,997 - $43,056
-832 Reduced 2.9%
27,836 $1.44 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $1.37 Million - $1.8 Million
-33,946 Reduced 54.21%
28,668 $1.19 Million
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $120,717 - $136,870
-2,516 Reduced 3.86%
62,614 $3.4 Million
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $135,356 - $161,517
-2,792 Reduced 4.11%
65,130 $3.34 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $29,466 - $32,947
-509 Reduced 0.74%
67,922 $3.94 Million
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $1.64 Million - $1.82 Million
-25,775 Reduced 27.36%
68,431 $4.38 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $271,043 - $320,954
-3,958 Reduced 4.03%
94,206 $6.78 Million
Q3 2022

Nov 16, 2022

BUY
$0.13 - $76.84 $12,761 - $7.54 Million
98,164 New
98,164 $6.98 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $55 - $32,810
-427 Closed
0 $6.98 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $7,334 - $8,077
-101 Reduced 19.13%
427 $33,000
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $6,209 - $7,445
101 Added 23.65%
528 $39,000
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $17,343 - $19,219
302 Added 241.6%
427 $26,000
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $6,151 - $8,023
125 New
125 $8,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Kayne Anderson Rudnick Investment Management LLC Portfolio

Follow Kayne Anderson Rudnick Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.